Engineered Cardiac Tissues as a Platform for CRISPR‐Based Mitogen Discovery

Abstract

Improved understanding of cardiomyocyte (CM) cell cycle regulation may allow researchers to stimulate pro‐regenerative effects in injured hearts or promote maturation of human stem cell‐derived CMs. Gene therapies, in particular, hold promise to induce controlled proliferation of endogenous or transplanted CMs via transient activation of mitogenic processes. Methods to identify and characterize candidate cardiac mitogens in vitro can accelerate translational efforts and contribute to the understanding of the complex regulatory landscape of CM proliferation and postnatal maturation. In this study, A CRISPR knockout‐based screening strategy using in vitro neonatal rat ventricular myocyte (NRVM) monolayers is established, followed by candidate mitogen validation in mature 3‐D engineered cardiac tissues (ECTs). This screen identified knockout of the purine metabolism enzyme adenosine deaminase (ADA‐KO) as an effective pro‐mitogenic stimulus. RNA‐sequencing of ECTs further reveals increased pentose phosphate pathway (PPP) activity as the primary driver of ADA‐KO‐induced CM cycling. Inhibition of the pathway's rate limiting enzyme, glucose‐6‐phosphate dehydrogenase (G6PD), prevented ADA‐KO induced CM cycling, while increasing PPP activity via G6PD overexpression increased CM cycling. Together, this study demonstrates the development and application of a genetic/tissue engineering platform for in vitro discovery and validation of new candidate mitogens affecting regenerative or maturation states of cardiomyocytes.